Home > Neurology > ECTRIMS 2019 > Optimising Long-Term Benefit of MS Treatment > Treatment response scoring systems to assess long term prognosis

Treatment response scoring systems to assess long term prognosis

Expert
Dr Jordi Río, University Hospital Vall d’Hebron, Barcelona, Spain
Conference
ECTRIMS 2019

DMTs may influence the natural history of MS [1]. “It is important to provide our patients information about long-term prognosis, during the first months of therapy”, Dr Jordi Río (University Hospital Vall d’Hebron, Barcelona, Spain) advised. Although different scoring systems have been used in the assessment of response in the short-term, little data exists regarding the long-term predictive power of these scores [2,3]. There is evidence that MRI activity, relapses, and EDSS worsening are good predictors of short-term treatment response, i.e. during the first 2-3 years after initiation of therapy [4]. Based on these clinical and imaging parameters, several scoring systems have been developed. Dr Río and colleagues compared different treatment response scoring systems to assess long-term prognosis in treated relapsing-remitting MS patients (n=319), and to describe diagnostic properties of the different scores.

Prediction model analysis showed that all scor...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on